Effects of HLA matching and panel reactive antibodies in the development of rejection after conversion of cyclosporine to azathioprine.
Zemel
S M
SM
Division of Nephrology, University of Maryland Hospital, Baltimore 21201.
Shen
S Y
SY
Weir
M R
MR
Dagher
F J
FJ
Bentley
F R
FR
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis*; D001379:Azathioprine / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis*; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology*; D006680:HLA Antigens / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use; D014184:Transplantation, Homologous
D000888:Antibodies, Anti-Idiotypic; D015415:Biomarkers; D003524:Cyclosporins; D006680:HLA Antigens; D001379:Azathioprine; D011241:Prednisone